Results 1 to 10 of about 10,060 (149)

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

International Journal of Infectious Diseases, 2021
Objectives: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia.
Alfredo Molteni, Daniele Generali, Valeria De Giuli   +2 more
exaly   +3 more sources

Canakinumab for systemic-onset juvenile idiopathic arthritis/Still's disease-effectiveness and safety data from the BiKeR registry. [PDF]

EULAR Rheumatol Open
: Objectives: In Germany, canakinumab is approved for the treatment of refractory systemic juvenile idiopathic arthritis (sJIA)/Still’s disease. This study assesses the experience of sJIA/Still’s disease patients treated with canakinumab in clinical ...
Horneff G, Kallinich T, Minden K, Dressler F, Hufnagel M, Weller-Heinemann F, Klein A.   +6 more
europepmc   +2 more sources

Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry. [PDF]

Front Pharmacol
ObjectiveThe primary aim of this study was to assess, in Still’s disease, whether the employment of canakinumab at a strictly on-label dose may increase the likelihood of treatment discontinuation due to study-defined long-term remission (LTR), compared ...
Vitale A, Caggiano V, Sbalchiero J, Lopalco G, Tufan A, Ragab G, Sfikakis PP, Dagna L, Batu ED, Ozen S, Conti F, Maiolini F, Bugatti S, Frassi M, Ruscitti P, Morrone M, La Torre F, Cakir IY, Akay N, Kilic Konte E, Laskari K, Bilginer Y, Gattamelata A, Croce J, De Stefano L, Voltarel G, Cipriani P, Maggio MC, Al-Mayouf SM, Fotis L, Rigante D, Sota J, Verrecchia E, Guggino G, La Barbera L, Piga M, Emmi G, Gallizzi R, Conti G, Sfriso P, Bartoloni E, Giacomelli R, Barone P, Olivieri AN, Alemanno A, Lo Gullo A, Direskeneli H, Alibaz-Oner F, Karamanakos A, Prete M, Edrees A, Gavioli F, Parronchi P, Ciccia F, Cardamone C, Hernández-Rodríguez J, Hatemi G, Bes C, Almaghlouth IA, Marhuenda ÁR, Gonzáles-García A, Gaggiano C, De Paulis A, Tezcan ME, Brucato AL, Feist E, Tornero-Romero F, Suzon B, Ogunjimi B, Thabet M, Conforti A, Pucino V, Boyarchuk O, Kovalchuk T, Govoni M, Iagnocco A, Chimenti MS, Moshrif A, Del Giudice E, Carubbi F, Erten Ş, Tharwat S, Hegazy MT, Więsik-Szewczyk E, Torres-Ruiz J, Martín-Nares E, Balistreri A, Fabiani C, Frediani B, Hinojosa-Azaola A, Kasapçopur Ö, Cantarini L.   +91 more
europepmc   +2 more sources

Effectiveness of Canakinumab for First-Line Steroid-Free Treatment in Systemic-Onset Juvenile Idiopathic Arthritis and Juvenile Still Disease. [PDF]

ACR Open Rheumatol
Objective This prospective study assesses the response to canakinumab monotherapy administered as three monthly subcutaneous injections in glucocorticoid‐naïve patients with newly diagnosed systemic juvenile idiopathic arthritis (sJIA) and Still disease ...
Horneff G, Kallinich T, Hufnagel M, Minden K, Weller-Heinemann F, Trauzeddel R, Foell D, Hinze C, Staubi F, Klein A.   +9 more
europepmc   +2 more sources

Efficacy and Safety of Canakinumab Compared With Standard Therapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC): A Systematic Review. [PDF]

Cancer Rep (Hoboken)
Background Lung cancer remains a leading cause of cancer‐related mortality worldwide, with few effective treatment options available for advanced stages.
Izadpanah K, Rezaei M, Nejadghaderi SA, Sharifi H.   +3 more
europepmc   +2 more sources

Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study. [PDF]

Rheumatol Ther
Introduction This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study.
Blank N, Schuetz C, Hufnagel M, Horneff G, Borte M, Kallinich T, Oommen PT, Janda A, Henes J, Weber-Arden J, Stock M, Kuemmerle-Deschner JB.   +11 more
europepmc   +2 more sources

Canakinumab and cardiovascular outcomes: results of the CANTOS trial

Journal of Community Hospital Internal Medicine Perspectives, 2018
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced in response to pathogen mediated tissue injury. Among the IL-1 cytokine family, IL-1 β results in upregulation of genes responsible for boosting immune ...
Syed Raza Shah
exaly   +2 more sources

Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States

Pediatric Rheumatology Online Journal, 2021
Background Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood.
Peter Hur, Kathleen G. Lomax, Raluca Ionescu-Ittu, Ameur M. Manceur, Jipan Xie, Jordan Cammarota, Raju Gautam, Navneet Sanghera, Nina Kim, Alexei A. Grom   +9 more
doaj   +1 more source

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases

Frontiers in Pediatrics, 2021
Anti-interleukin 1 agents are used successfully in colchicine-resistant or intolerant Familial Mediterranean Fever (FMF) patients. Sixty-five patients with FMF who received canakinumab treatment for at least 6 months due to colchicine resistance or ...
Burcu Bozkaya Yücel, Ozlem Aydog, Ozlem Aydog, Hulya Nalcacioglu, Ayşegül Yılmaz   +4 more
doaj   +1 more source

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

Frontiers in Pediatrics, 2022
ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS.
Mikhail M. Kostik, Eugenia A. Isupova, Konstantin Belozerov, Tatyana S. Likhacheva, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Rinat Raupov, Vera V. Masalova, Irina A. Chikova, Margarita F. Dubko, Olga V. Kalashnikova, Vyacheslav G. Chasnyk, Randy Q. Cron   +13 more
doaj   +1 more source